Publications by authors named "Fiona Herbst"
Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC), only a subset of patients will respond due to a heterogenous tumor microenvironment. KEYNOTE-495/KeyImPaCT is an ongoing biomarker-directed, adaptively randomized phase 2 study investigating first-line pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily), anti-CTLA-4 quavonlimab (25 mg every 6 weeks) or anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks) in advanced NSCLC. Patients were categorized by T-cell-inflamed gene expression profile (TcellGEP) and tumor mutational burden (TMB) status and randomly assigned 1:1:1 to receive pembrolizumab + lenvatinib, pembrolizumab + quavonlimab or pembrolizumab + favezelimab.
View Article and Find Full Text PDFArticle Synopsis
- - The CheckMate 401 study aimed to evaluate the safety and effectiveness of combining nivolumab and ipilimumab, followed by nivolumab alone, in patients with advanced melanoma who historically have had poor outcomes.
- - A total of 533 treatment-naive patients with unresectable stage III-IV melanoma were analyzed, revealing incidences of severe adverse events and varying overall survival rates across different patient subgroups.
- - Results suggested the treatment was generally tolerable, with a 24-month overall survival rate of 63%, but efficacy was notably lower in patients with poorer performance status and specific melanoma subtypes, indicating a need for new treatment strategies.
Lung cancer continues to be a major global health problem; the disease is diagnosed in more than 1.6 million new patients each year. However, significant progress is underway in both the prevention and treatment of lung cancer.
View Article and Find Full Text PDF